Cardiovascular diseases (CVDs) remain the leading cause of mortality and morbidity, underscoring the urgent need for innovative research and transformative clinical solutions. The field of cardiovascular health encompasses a vast spectrum of scientific inquiry and clinical practice—from molecular mechanisms to population-level interventions, from risk factor exploration to the management of end-stage clinical events. Historically, cardiovascular research has been segmented into basic, clinical, and epidemiological disciplines. Yet, as these domains rapidly evolve, there is a growing need for a unified platform to disseminate paradigm-shifting discoveries that bridge gaps and improve outcomes. To meet this critical need, we launched npj Cardiovascular Health in March 2024. As a Nature Partner Journal, we are dedicated to publishing high-impact, interdisciplinary research spanning the full continuum of cardiovascular science—from bench to bedside and beyond.
Since the launch of npj Cardiovascular Health, the journal has served as an open-access forum for rigorously peer-reviewed, pioneering work that reflects the diversity of the field. Our published original research addresses pressing clinical questions in CVD diagnosis, treatment, prognosis, and etiology. For instance, AI-driven approaches leveraging multimodal or multi-omics data have advanced clinical screening, diagnosis, and prediction1,2,3,4. A translational framework was also developed for genoproteomic studies for cardiovascular drug discovery5. In therapeutics, an observational study was conducted to investigate the relationship between proton pump inhibitors and the risk of gastrointestinal bleeding in oral anticoagulant users6, while a pragmatic clinical trial evaluated the efficacy of obesity treatments in primary care settings7. Prognostic insights have emerged from studies identifying risk factors for cardiovascular outcomes associated with COVID-19 and linking gut microbiota metabolism to poor outcomes8,9,10. Additionally, novel risk factors for coronary artery disease, heart failure, atrial fibrillation, valvular heart diseases, and aortic stenosis have been elucidated11,12,13,14,15. These contributions underscore our commitment to unraveling the causes, prevention, and management of CVDs through clinically relevant innovation. Beyond original research, we have curated reviews synthesizing advancements across a broad range of conditions, including acute coronary syndrome, chronic coronary disease, heart failure, stroke, atrial fibrillation, atrial cardiomyopathy, and acute aortic dissection16,17,18,19,20,21,22,23,24,25,26. These articles reflect the latest scientific progress and diverse perspectives shaping cardiovascular health today.
To accelerate collaboration, we have launched nine thematic Collections, uniting researchers across disciplines to tackle specific challenges. npj Cardiovascular Health actively promotes dialogue across specialties, as seen in our collection —“Digital Health Technologies: An Evolving Paradigm in the Transformation of Cardiovascular Care”. We also prioritize studies addressing unmet needs in the collections, such as women’s cardiovascular health across the lifespan and the pursuit of novel therapeutic targets.
As an open-access journal, we ensure that knowledge reaches clinicians, researchers, and policymakers without barriers. Our editorial team, led by experts in cardiology, translational medicine, and epidemiology, is committed to a fair and rigorous review process that upholds the highest standards of scientific integrity. Looking ahead, npj Cardiovascular Health aspires to be a catalyst for progress in a field that impacts millions of lives worldwide. We invite submissions that challenge conventions, leverage cross-disciplinary collaborations, and advance equity in cardiovascular care. It is an honor to serve as the founding Editor-in-Chief of this journal. I look forward to working together with a global community dedicated to a brighter future for cardiovascular health.
References
Ratman, D. et al. Polygenic risk scores improve CAD risk prediction in individuals at borderline and intermediate clinical risk. npj Cardiovasc. Health 2, 13 (2025).
Kim, Y. et al. Multimodal AI-approach for the automatic screening of cardiovascular diseases based on nocturnal physiological signals. npj Cardiovasc. Health 2, 15 (2025).
Mathew, G. et al. Foundation models for cardiovascular disease detection via biosignals from digital stethoscopes. npj Cardiovasc. Health 1, 25 (2024).
Rau, A. et al. Deep learning to predict cardiovascular mortality from aortic disease in heavy smokers. npj Cardiovasc. Health 1, 28 (2024).
Yang, Z. et al. A translational framework of genoproteomic studies for cardiovascular drug discovery. npj Cardiovasc. Health 1, 12 (2024).
Wang, Z. et al. The association between proton pump inhibitors and the risk of gastrointestinal bleeding in oral anticoagulants users. npj Cardiovasc. Health 2, 11 (2025).
Goldstein, C. M. et al. Pragmatic online obesity treatment in primary care: a hybrid randomized clinical trial of implementation strategies. npj Cardiovasc. Health 1, 29 (2024).
Zidar, D. A. et al. Pre-exposure immunohematologic features of heart failure associate with COVID-19 mortality. npj Cardiovasc. Health 1, 32 (2024).
Yu, Q. et al. Risk factors for long-term cardiovascular post-acute sequelae of COVID-19 infection: A nested case-control study in Hong Kong. npj Cardiovasc. Health 1, 10 (2024).
Liu, Y. et al. Gut microbiota metabolism disturbance is associated with postoperative atrial fibrillation after coronary artery bypass grafting. npj Cardiovasc. Health 1, 5 (2024).
Zhao, J. V. & Zhang, J. Using proteomics to identify the mechanisms underlying the benefits of statins on ischemic heart disease. npj Cardiovasc. Health 1, 15 (2024).
William, S. et al. A systematic review to identify assessment instruments for social isolation or loneliness in adults with heart failure. npj Cardiovasc. Health 2, 10 (2025).
Xu, J. et al. Unveiling the shared etiology between gastrointestinal disorders and valvular heart diseases through a genome-wide pleiotropy study. npj Cardiovasc. Health 2, 17 (2025).
Song, W. et al. Association between brachial-ankle pulse wave velocity and the risk of new-onset atrial fibrillation: A report from Kailuan prospective cohort study. npj Cardiovasc. Health 1, 1 (2024).
Zhao, Q. et al. Genetic association of serum calcium, phosphate, vitamin D, parathyroid hormone, and FGF23 with the risk of aortic stenosis. npj Cardiovasc. Health 1, 13 (2024).
Tan, Q. et al. Intravascular imaging for acute coronary syndrome. npj Cardiovasc. Health 2, 18 (2025).
Wang, L. et al. Role of biomechanical factors in plaque rupture and erosion: insight from intravascular imaging based computational modeling. npj Cardiovasc. Health 2, 12 (2025).
Rejeleene, R. et al. Addressing myocardial infarction in South-Asian populations: risk factors and machine learning approaches. npj Cardiovasc. Health 2, 4 (2025).
Krittanawong, C. et al. Strategies for chronic coronary disease: A brief guide for clinicians. npj Cardiovasc Health 1, 6 (2024).
Baudry, G. et al. Consistency of HFrEF treatment effect in underrepresented groups in randomized clinical trials. npj Cardiovasc. Health 1, 27 (2024).
Silva, G. S. et al. Blood pressure management to prevent recurrent stroke: current evidence and perspectives. npj Cardiovasc. Health 1, 18 (2024).
Sweat, M. E. & Pu, W. T. Genetic and molecular underpinnings of atrial fibrillation. npj Cardiovasc. Health 1, 35 (2024).
Pu, J. & Du, Y. Recent advances in understanding the roles of T cells in atrial fibrillation. npj Cardiovasc. Health 1, 23 (2024).
Gorrie, N. et al. Atrial cardiomyopathy in cardiac amyloidosis: clinical imaging and manifestations. npj Cardiovasc. Health 2, 8 (2025).
Spencer, L. W. et al. Atrial cardiomyopathy in endurance athletes. npj Cardiovasc. Health 1, 30 (2024).
Hasan, M. T. et al. Acute Type A aortic dissection surgical repair in Octogenarians: A meta-analysis. npj Cardiovasc. Health 1, 16 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.L. is Editor in Chief of npj Cardiovascular Health. The author declares no other competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Liu, J. Advancing global cardiovascular research and clinical translation. npj Cardiovasc Health 2, 43 (2025). https://doi.org/10.1038/s44325-025-00085-3
Received:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1038/s44325-025-00085-3